CN113713028A - Composition with effect of inhibiting activity of tumor cells and application thereof - Google Patents
Composition with effect of inhibiting activity of tumor cells and application thereof Download PDFInfo
- Publication number
- CN113713028A CN113713028A CN202111109677.5A CN202111109677A CN113713028A CN 113713028 A CN113713028 A CN 113713028A CN 202111109677 A CN202111109677 A CN 202111109677A CN 113713028 A CN113713028 A CN 113713028A
- Authority
- CN
- China
- Prior art keywords
- extract
- composition
- extracting
- group
- coprinus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/35—Extraction with lipophilic solvents, e.g. Hexane or petrol ether
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention provides a composition with the function of inhibiting the activity of tumor cells and application thereof, wherein the composition comprises the following components: natural capsaicin, diosgenin, coprinus japonicus extract, Chimonanthus praecox volatile oil extract, saussurea involucrate extract and Simarouba chinensis extract. The composition is all taken from natural medicinal plants, the antitumor active ingredients extracted and separated from the natural plants have the characteristics of numerous quantities, diversified structural types, remarkable drug effect and the like, and the characteristics of diversified antitumor activity and multi-target effect are not lost as an antitumor drug research and development idea and a potential strategy.
Description
Technical Field
The invention belongs to the field of antitumor drugs, and particularly relates to a composition with a tumor cell activity inhibiting effect and application thereof.
Background
Human choriocarcinoma is a highly malignant trophoblastic tumor, blood metastasis occurs in the secondary early stage, and the human choriocarcinoma has sensitivity and drug resistance to chemotherapeutic drugs.
Disclosure of Invention
In view of the above, the present invention aims to provide a composition having an effect of inhibiting tumor cell activity and an application thereof.
The invention provides a composition with the function of inhibiting the activity of tumor cells, which comprises the following components: natural capsaicin, diosgenin, coprinus japonicus extract, Chimonanthus praecox volatile oil extract, saussurea involucrate extract and Simarouba chinensis extract.
In the invention, the mass ratio of the natural capsaicin, the diosgenin, the coprinus japonicas extract, the Chimonanthus praecox volatile oil extract, the saussurea involucrata extract and the singletree extract is (0.9-1.1): (0.47-0.52): (0.18-0.23): (0.48-0.53): 0.45-0.55).
In the invention, the mass ratio of the natural capsaicin to the diosgenin to the coprinus comatus extract to the Chimonanthus praecox volatile oil extract to the saussurea involucrata extract to the singletree extract is 1:1:0.5:0.2:0.5: 0.5.
In the invention, the natural capsaicin plays an anti-tumor role in the aspects of induction cycle retardation, proliferation invasion inhibition, autophagy apoptosis regulation and the like of tumor cells. The diosgenin plays a role in inhibiting the activity of tumor cells mainly through mechanisms of regulating and controlling a signal path to retard the growth and migration of the tumor cells, activating the expression of cancer suppressor genes to promote the apoptosis of the tumor cells, down-regulating tumor growth enzymes to cut off the proliferation of the tumor cells and the like. The Podophyllum japonicum extract is obtained from whole plant of Aranea belonging to Araliaceae perennial bulb herbaceous plant of Liliales, and contains alkaloid as main ingredient; the total alkaloids of canna has obvious cytotoxic and inhibitory effects on various cancer cells, and has inhibitory effects on human melanoma, leukemia cells, pancreatic cancer cells and the like. The volatile oil extract of radix Chimonanthi Praecocis is extracted from root of radix Chimonanthi Praecocis of Chimonanthi of Ranunculaceae, and its antitumor activity is mainly concentrated in volatile oil and amino acids, wherein the lipid chemical component in the volatile oil mainly exerts antitumor activity by inhibiting ion transport. The extract is obtained from whole plant of saussurea involucrate of perennial herb of saussurea of Compositae, and its active ingredients comprise sterol compounds, flavonoid compounds, amide compounds, etc. Wherein, the flavonoid compounds promote the secretion of interferon by regulating a signal path, thereby inhibiting the growth of tumors. The extract of the single root is taken from the rhizome of shrub of the genus Ervatamia of the family Apocynaceae, contains various chemical components such as alkaloid, lignin, terpenoid and the like, and researches show that indole alkaloid in the extract has obvious inhibition effect on the growth of human oral epidermoid carcinoma cells.
In the invention, the natural capsaicin exists in the form of freeze-dried powder; the freeze-dried powder is prepared by the following method:
mixing insoluble natural capsaicin and a solubilizing component A, dissolving in water, and freeze-drying to obtain freeze-dried powder;
the solubilizing component A comprises one or more of PEG400, hydroxypropyl betacyclodextrin, hydroxyethyl betacyclodextrin, methyl betacyclodextrin and sulfobutyl betacyclodextrin sodium.
In the invention, the diosgenin exists in the form of freeze-dried powder; the freeze-dried powder is prepared by the following method:
mixing the insoluble diosgenin and the solubilizing component B, dissolving in water, and freeze-drying to obtain lyophilized powder.
In the present invention, the coprinus japonicus extract is prepared according to the following method:
pulverizing whole plant of Coprinus cinereus, extracting with 95% ethanol as extraction solvent by continuous reflux method, concentrating into extract, dispersing in water, extracting with ethyl acetate and n-butanol respectively, collecting two-phase solvent, spin drying, and mixing to obtain Coprinus cinereus dry extract.
In the invention, the volatile oil extract of the chopsticks is prepared by the following steps:
crushing the rhizome of the plant of Chimonanthus praecox, and extracting for 9.5-10.5 h by using a steam extraction method to obtain the volatile oil extract of the Chimonanthus praecox.
In the invention, the saussurea involucrate extract is prepared by the following method:
pulverizing the whole plant of saussurea involucrata, extracting with 80% ethanol as extraction solvent, concentrating into extract, dispersing in water, extracting with n-butanol, and spin drying to obtain saussurea involucrata extract.
In the present invention, the single-root wood extract is preferably prepared according to the following method:
pulverizing rhizome of Monostroma nitidum plant, extracting with 95% ethanol as extraction solvent by continuous reflux method, concentrating into extract, dispersing in water, extracting with petroleum ether and ethyl acetate respectively, collecting two-phase solvent, spin drying, and mixing to obtain Monostroma nitidum extract.
The invention provides an application of the composition in the technical scheme in preparation of antitumor drugs.
The invention provides a composition with the function of inhibiting the activity of tumor cells, which comprises the following components: natural capsaicin, diosgenin, coprinus japonicus extract, Chimonanthus praecox volatile oil extract, saussurea involucrate extract and Simarouba chinensis extract. The composition is all taken from natural medicinal plants, the antitumor active ingredients extracted and separated from the natural plants have the characteristics of numerous quantities, diversified structural types, remarkable drug effect and the like, and the characteristics of diversified antitumor activity and multi-target effect are not lost as an antitumor drug research and development idea and a potential strategy.
Detailed Description
In order to further illustrate the present invention, the following examples are provided to describe a composition having an effect of inhibiting tumor cell activity and its application in detail, but they should not be construed as limiting the scope of the present invention.
Comparative example
Example 1
Preparation of the composition
The embodiment provides a composition with the effect of inhibiting the activity of tumor cells, wherein the active ingredients of the composition comprise the following components in parts by weight: 1 part of natural capsaicin, 1 part of diosgenin, 0.5 part of coprinus comatus extract, 0.2 part of Chimonanthus praecox volatile oil extract, 0.5 part of saussurea bracteata extract and 0.5 part of single-root woodlouse extract.
This example further provides methods for preparing the six active ingredients of the above-described compositions.
1 part of slightly soluble natural capsaicin and 19 parts of sulfobutyl-beta-cyclodextrin sodium are dissolved in a proper amount of aqueous solution and then freeze-dried into powder.
Dissolving insoluble diosgenin 1 part and Pluronic F68 39 parts in water solution, and freeze drying to obtain powder.
Coprinus comatus extract: pulverizing whole plant of Podophyllum japonicum Thunb, extracting with appropriate amount of 95% ethanol as extraction solvent under continuous reflux for 10 hr, rotary evaporating and concentrating to obtain 10:1 extract, dispersing the extract with appropriate amount of water, extracting with ethyl acetate and n-butanol respectively, collecting two-phase solvent, spin drying, and mixing to obtain Podophyllum japonicum dry extract.
The volatile oil extract of the Chimonanthus praecox comprises the following components: pulverizing rhizome of Chimonanthus praecox, and extracting with water vapor for 10 hr to obtain yellow oily extract with special fragrance.
Saussurea involucrate extract: pulverizing the whole plant of saussurea involucrata, extracting for 10h by using a proper amount of 80% ethanol as an extraction solvent, filtering by using gauze, taking an extracting solution, performing rotary evaporation to obtain an extract with a ratio of 30:1, dispersing the extract by using a proper amount of water, extracting by using n-butanol, and taking n-butanol phase for rotary drying to obtain the dry paste extract of the saussurea involucrata.
Single wood extract: pulverizing rhizome of Sinomenium acutum plant, extracting with 95% ethanol as extraction solvent for 10 hr, spin-drying and concentrating to obtain 10:1 extract, dispersing the extract with appropriate amount of water, extracting with petroleum ether and ethyl acetate respectively, collecting two-phase solvent, spin-drying and mixing to obtain Sinomenium acutum dry extract.
Respectively sequentially mixing the 6 active components prepared in the above steps according to the weight ratio of 1 part: 1 part of: 0.5 part: 0.2 part of: 0.5 part: 0.5 part by weight to obtain a composition.
Cell experiments
Taking 1 part of the composition of the invention, dissolving the composition in 500 parts of deionized water, and finally diluting the composition with 500 parts of RPMI-1640 culture solution to obtain the composition with the effect of inhibiting the activity of tumor cells.
Cell assay 1: CCK8 method for detecting inhibition effect of composition on human choriocarcinoma cell proliferation
Culturing human choriocarcinoma cells: inoculating human choriocarcinoma cells into RPMI-1640 culture medium containing 5% fetal calf serum, incubating in 5% carbon dioxide culture box at 37 deg.C, and subculturing for 1 time about 2 days. Digesting human chorionic carcinoma cells in logarithmic growth phase with 0.25% pancreatin, and regulating cell suspension density to 1.5X 10 with culture medium4Inoculating each cell/mL into a 96-well cell culture plate, adding 100 mu L of cell suspension into each well, culturing under the incubator condition until the cells grow out and adhere to the wall in a single layer, sucking and removing supernatant, and washing for 2 times by using phosphate buffer to obtain the human choriocarcinoma cell in-vitro culture.
Experiment design: the human chorionic carcinoma cell in-vitro culture is divided into an experimental group, a negative control group, a positive control group and a blank group. The experimental group was added with the composition diluted with RPMI-1640 medium, and 25. mu.L, 50. mu.L, 75. mu.L, and 100. mu.L, respectively, and 6 duplicate wells were set for each concentration. The negative control group was compared with the experimental group, and the composition was not added, and the rest were unchanged. In the positive control group, compared with the experimental group, the composition was replaced with 100. mu.L of 25mg/mL fluorouracil injection, and the rest was unchanged. Compared with the experimental group, the blank group had no human choriocarcinoma cells, and the rest were unchanged. The four groups were incubated in an incubator with 5% carbon dioxide at 37 ℃ for 2 days, and the supernatant was aspirated and washed 2 times with phosphate buffer.
Operation before detection: the four groups were added with 20. mu.L of CCK-8 solution and 80. mu.L of RPMI-1640 culture medium, respectively, and cultured for 30 min. The absorbance (OD) at 450nm of each well and the survival rate of cancer cells were measured by a microplate reader (OD experiment-OD blank)/(OD control-OD blank) × 100). The survival results for different groups of human choriocarcinoma cells are shown in the following table.
The data were analyzed using SPSS (version 23.0) statistical software, the data were measured using the "mean. + -. standard deviation (X. + -.S)," single factor analysis of variance was used for the mean comparison between groups, single sample t test was used for the mean comparison between two groups, and P < 0.05 indicated that the difference was statistically significant.
TABLE 1 survival results of different groups of human chorionic carcinoma cells by CCK8 method
| Group of | Survival rate% |
| Experimental group 25. mu.L | 98.86±5.87 |
| Experimental group 50. mu.L | 68.78±3.64 |
| Experimental group 75 μ L | 46.87±6.14 |
| Experimental group 100 μ L | 28.97±4.73 |
| Negative control group | 102.06±4.68 |
| Positive control group | 23.57±6.47 |
| Blank group | 8.28±0.78 |
The experimental results show that the cell survival rates of the experimental groups of 50 ul, 75 ul and 100 ul are obviously lower than those of the negative control group, the statistical significance is achieved (P is less than 0.05) compared with the negative control group, and the cell survival rate values show the trend of gradually decreasing with the increase of the addition amount of the composition, so that the obvious dose-effect relationship is presented.
Cell experiment 2: MTT method for detecting inhibition effect of composition on human choriocarcinoma cell proliferation
Culturing human choriocarcinoma cells: the same procedure as described above.
Experiment design: the human chorionic carcinoma cell in-vitro culture is divided into an experimental group, a negative control group, a positive control group and a blank group. The experimental group was added with the composition diluted with RPMI-1640 medium, and 25. mu.L, 50. mu.L, 75. mu.L, and 100. mu.L, respectively, and 6 duplicate wells were set for each concentration. The negative control group was compared with the experimental group, and the composition was not added, and the rest were unchanged. In the positive control group, compared with the experimental group, the composition was replaced with 100. mu.L of 25mg/mL fluorouracil injection, and the rest was unchanged. Compared with the experimental group, the blank group had no human choriocarcinoma cells, and the rest were unchanged. The four groups were incubated in an incubator with 5% carbon dioxide at 37 ℃ for 2 days, and the supernatant was aspirated and washed 2 times with phosphate buffer.
Operation before detection: the four groups were incubated for 4 hours with 20. mu.L of MTT solution and 80. mu.L of RPMI-1640 medium, respectively, and the supernatant was removed by aspiration. The crystals were dissolved by adding 100. mu.L of dimethyl sulfoxide to each group and shaking. The absorbance (OD) at 490nm of each well and the survival rate of cancer cells were measured using a microplate reader (OD experiment-OD blank)/(OD control-OD blank) × 100). The survival results for different groups of human choriocarcinoma cells are shown in the following table.
TABLE 2 survival results of different groups of human choriocarcinoma cells in MMT method
| Group of | Survival rate% |
| Experimental group 25. mu.L | 96.82±3.87 |
| Experimental group 50. mu.L | 72.71±4.72 |
| Experimental group 75 μ L | 54.18±3.76 |
| Experimental group 100 μ L | 35.28±4.17 |
| Negative control group | 105.00±3.81 |
| Positive control group | 29.79±4.27 |
| Blank group | 5.98±2.47 |
The results show that the experimental groups of 50. mu.l, 75. mu.l and 100. mu.l have influence on the survival rate of choriocarcinoma cells compared with the negative control group, the difference has statistical significance (P is less than 0.05), the survival rate of the cells treated by the composition is obviously lower than that of the negative control group, and the cell survival rate value shows a trend of gradually decreasing with the increase of the addition amount of the composition, so that the dose-effect relationship is obvious.
Animal testing
Respectively taking 1 part, 5 parts and 10 parts of the composition, dissolving the composition with water for injection, diluting the composition to 100 parts, filtering the solution by using a 0.22-micron filter membrane, subpackaging the solution in an ampoule, and sterilizing the solution for 30min at 115 ℃ under a hot pressure to obtain sterile composition diluent with the concentration of 1 time, 5 times and 10 times.
Selecting SCID mouse, shaving and sterilizing back hair, injecting 0.3ml JEG-3 cell suspension into right back of mouse with sterile skin test needle, feeding in clean room, and allowing the tumor to grow to 100mm after the incubation period of transplanted tumor3After that, namelyObtaining the tumor-bearing mice. 25 tumor-bearing mice were randomly divided into 5 groups of 5 mice each. The administration is carried out by adopting an intraperitoneal injection mode:
group A mice were injected with 500. mu.L of sterile physiological saline (negative control group).
Group B mice were injected with 500. mu.L of a 1-fold concentration of sterile composition diluent.
Group C mice were injected with 500. mu.L of 5-fold concentration of sterile composition diluent.
Group D mice were injected with 500. mu.L of 10-fold concentration of sterile composition diluent.
Group E mice were injected with 500. mu.L of fluorouracil injection (positive control) at a concentration of 25 mg/mL.
And (3) treatment after administration: the mouse subcutaneous graft tumor length a and length b were measured on day 14 with a vernier caliper, using the formula v (mm) ═ 1/2 a b2The volume of the transplanted tumor was calculated, and then the volume inhibition rate of the transplanted tumor was calculated for each administration group: (1-mean volume increase of transplants per group/mean volume increase of transplants in negative control group) × 100%.
TABLE 3 graft tumor inhibition rates of the groups after administration of the compositions
| Group of | Volume (mm)3) | Volume inhibition ratio% |
| Group A (negative control group) | 4359.35±158.98 | — |
| Group B | 4087.14±89.73 | 6.24％ |
| Group C | 3687.18±124.38 | 15.42％ |
| Group D | 2368.94±137.24 | 45.66％ |
| Group E (positive control group) | 469.58±48.25 | 89.23％ |
As can be seen from the experimental results, the administration mode of the fluorouracil injection has the highest inhibition rate on the transplanted tumor; meanwhile, the statistical result shows that the group C and the group D have obvious difference (P is less than 0.05) compared with the group A of the negative control group, which indicates that the composition of the invention has obvious dose-effect relationship on the inhibition rate of the transplanted tumor.
Comparative example 1
Preparation of the composition: the "example 1: composition preparation "the three active ingredients (example 1 is in the form of six compositions) of the natural capsaicin, the diosgenin and the coprinus comatus extract prepared in the preparation method are sequentially mixed according to the weight ratio of 1 part: 1 part of: 0.5 part by weight to obtain a composition.
Cell experiments
Taking 1 part of the composition of the comparative example, dissolving the composition in 500 parts of deionized water, and finally diluting the solution with 500 parts of RPMI-1640 culture solution to obtain the composition with the effect of inhibiting the activity of the tumor cells.
Cell assay 1: the CCK8 method is used for detecting the inhibition effect of the composition on human choriocarcinoma cell proliferation.
Culturing human choriocarcinoma cells: the same as in example 1.
Experiment design: the human chorionic carcinoma cell in-vitro culture is divided into an experimental group, a negative control group, a positive control group and a blank group. The experimental group was added with the composition diluted with RPMI-1640 medium, and 75. mu.l, 100. mu.l, 150. mu.l, 200. mu.l, respectively, and 6 duplicate wells were set for each concentration. The negative control group was compared with the experimental group, and the composition was not added, and the rest were unchanged. In the positive control group, the composition was replaced with 100. mu.l of 25mg/ml fluorouracil injection, and the rest was unchanged, compared with the experimental group. Compared with the experimental group, the blank group had no human choriocarcinoma cells, and the rest were unchanged. The four groups were incubated in an incubator with 5% carbon dioxide at 37 ℃ for 2 days, and the supernatant was aspirated and washed 2 times with phosphate buffer.
Operation before detection: the same as in example 1. The survival results for different groups of human choriocarcinoma cells are shown in the following table.
TABLE 4 survival results of different groups of human chorionic carcinoma cells by CCK8 method
| Group of | Survival rate% |
| Experimental group 75. mu.l | 96.15±2.23 |
| Experimental group 100. mu.l | 97.76±6.17 |
| Experimental group 150. mu.l | 86.27±4.37 |
| Experimental group 200. mu.l | 72.86±3.34 |
| Negative control group | 103.79±5.73 |
| Positive control group | 26.47±4.83 |
| Blank group | 9.78±3.38 |
As can be seen from the experimental results, the addition of 200ul of the composition in the experimental group significantly reduced the survival rate of choriocarcinoma cells compared to the other addition amounts, and the difference was statistically significant (P < 0.05) compared to the negative control group. Compared with the example 1, the addition amount of the composition is increased to 200 mu l to show obvious inhibition effect on choriocarcinoma cells, and the preliminary analysis shows that the composition of the comparative example 1 only contains three active components, while the example 1 contains six active components, and the synergistic effect of the six active components is stronger than that of the three active components.
Cell experiment 2: MTT method for detecting inhibition effect of composition on human choriocarcinoma cell proliferation
Culturing human choriocarcinoma cells: the same as in example 1.
Experiment design: the same procedure as described above.
Operation before detection: the same procedure as described above. The survival results for different groups of human choriocarcinoma cells are shown in the following table.
TABLE 5 survival results of different groups of human choriocarcinoma cells in MMT method
The experimental result shows that 200 mu l of the experimental group has influence on the survival rate of choriocarcinoma cells, the statistical analysis shows that the difference between the experimental group and the negative control group is obvious (P is less than 0.05), and the detection result of the MMT method is parallel to the detection result of the CCK8 method.
Comparative example 2
Preparation of the composition: the "example 1: composition preparation the four active ingredients (example 1 is in the form of six compositions) of the natural capsaicin, the Chimonanthus praecox volatile oil extract, the saussurea involucrata extract and the Simmondsia chinensis extract prepared in the preparation are sequentially mixed according to the weight ratio of 1 part: 0.2 part: 0.5 part to obtain the composition.
Cell experiments
Taking 1 part of the composition of the comparative example, dissolving the composition in 500 parts of deionized water, and finally diluting the solution with 500 parts of RPMI-1640 culture solution to obtain the composition with the effect of inhibiting the activity of the tumor cells.
Cell assay 1: the CCK8 method is used for detecting the inhibition effect of the composition on human choriocarcinoma cell proliferation.
Culturing human choriocarcinoma cells: the same as in example 1.
Experiment design: the human chorionic carcinoma cell in-vitro culture is divided into an experimental group, a negative control group, a positive control group and a blank group. The experimental group was added with the composition diluted with RPMI-1640 medium, 50. mu.l, 75. mu.l, 100. mu.l, 150. mu.l, respectively, and 6 duplicate wells were set for each concentration. The negative control group was compared with the experimental group, and the composition was not added, and the rest were unchanged. In the positive control group, the composition was replaced with 100. mu.l of 25mg/ml fluorouracil injection, and the rest was unchanged, compared with the experimental group. Compared with the experimental group, the blank group had no human choriocarcinoma cells, and the rest were unchanged. The four groups were incubated in an incubator with 5% carbon dioxide at 37 ℃ for 2 days, and the supernatant was aspirated and washed 2 times with phosphate buffer.
Operation before detection: the same as in example 1. The survival results for different groups of human choriocarcinoma cells are shown in the following table.
TABLE 6 survival results of different groups of human chorionic carcinoma cells by CCK8 method
| Group of | Survival rate% |
| Experimental group 50. mu.l | 98.81±3.83 |
| Experimental group 75. mu.l | 87.65±4.63 |
| Experimental group 100. mu.l | 83.71±5.75 |
| Experimental group 150. mu.l | 73.58±5.76 |
| Negative control group | 104.67±3.75 |
| Positive control group | 20.86±5.39 |
| Blank group | 12.18±2.34 |
As can be seen from the experimental results, the amounts of 75. mu.l, 100. mu.l and 150. mu.l of the compositions added in the experimental groups had significant inhibitory effects on choriocarcinoma cells, and were statistically different (P < 0.05) from those in the negative control group. Compared with the comparative example 1, the composition of the comparative example 2 is added with one active ingredient, and the tumor inhibiting activity of the composition is enhanced. Compared with the example 1, the composition reduces two active ingredients, but the effect of inhibiting the tumor activity is still obvious.
Animal testing
Respectively taking 1 part, 5 parts and 10 parts of the composition, dissolving the composition with water for injection, diluting the composition to 100 parts, filtering the solution by using a 0.22-micron filter membrane, subpackaging the solution in an ampoule, and sterilizing the solution for 30min at 115 ℃ under a hot pressure to obtain sterile composition diluent with the concentration of 1 time, 5 times and 10 times.
Establishing a JEG-3 human choriocarcinoma cell mouse transplantation tumor model: the same as in example 1.
The tumorigenic mice were divided into 5 groups of 5 mice each. The administration is carried out by adopting an intraperitoneal injection mode:
group A mice were injected with 500. mu.L of sterile physiological saline (negative control group).
Group B mice were injected with 500. mu.L of a 1-fold concentration of sterile composition diluent.
Group C mice were injected with 500. mu.L of 5-fold concentration of sterile composition diluent.
Group D mice were injected with 500. mu.L of 10-fold concentration of sterile composition diluent.
Group E mice were injected with 500. mu.L of fluorouracil injection (positive control) at a concentration of 25 mg/mL.
And (3) treatment after administration: the same as in example 1.
TABLE 7 graft tumor inhibition rates of the groups after administration of the compositions
The experimental results show that the group using fluorouracil injection has the strongest tumor inhibition activity, the group D of the comparative example also has obvious tumor inhibition activity, the difference compared with the negative control group has statistical significance (P is less than 0.05), and the inhibition rate is similar to that of the example 1. The results show that the composition of the four active ingredients of the present example still has a certain antitumor activity, but has a less synergistic effect (P < 0.05) than the six active ingredients of example 1.
As can be seen from the above examples, the present invention provides a composition with tumor cell activity inhibiting effect, which comprises the following components: natural capsaicin, diosgenin, coprinus japonicus extract, Chimonanthus praecox volatile oil extract, saussurea involucrate extract and Simarouba chinensis extract. The composition is all taken from natural medicinal plants, the antitumor active ingredients extracted and separated from the natural plants have the characteristics of numerous quantities, diversified structural types, remarkable drug effect and the like, and the characteristics of diversified antitumor activity and multi-target effect are not lost as an antitumor drug research and development idea and a potential strategy.
The foregoing is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, various modifications and decorations can be made without departing from the principle of the present invention, and these modifications and decorations should also be regarded as the protection scope of the present invention.
Claims (10)
1. A composition with effect of inhibiting tumor cell activity comprises the following components: natural capsaicin, diosgenin, coprinus japonicus extract, Chimonanthus praecox volatile oil extract, saussurea involucrate extract and Simarouba chinensis extract.
2. The composition as claimed in claim 1, wherein the mass ratio of the natural capsaicin, the diosgenin, the coprinus japonicus extract, the Chimonanthus praecox volatile oil extract, the saussurea involucrate extract and the Sinomenium acutum extract is 1 (0.9-1.1): 0.47-0.52): 0.18-0.23): 0.48-0.53): 0.45-0.55.
3. The composition according to claim 1, wherein the mass ratio of the natural capsaicin, the diosgenin, the coprinus japonicus extract, the Chimonanthus praecox volatile oil extract, the saussurea involucrate extract and the Sinomenium acutum extract is 1:1:0.5:0.2:0.5: 0.5.
4. The composition as claimed in claim 1, wherein the native capsaicin is present in the form of a lyophilized powder; the freeze-dried powder is prepared by the following method:
mixing insoluble natural capsaicin and a solubilizing component A, dissolving in water, and freeze-drying to obtain freeze-dried powder;
the solubilizing component A comprises one or more of PEG400, hydroxypropyl betacyclodextrin, hydroxyethyl betacyclodextrin, methyl betacyclodextrin and sulfobutyl betacyclodextrin sodium.
5. The composition according to claim 1, wherein the diosgenin is present in the form of a lyophilized powder; the freeze-dried powder is prepared by the following method:
mixing the insoluble diosgenin and the solubilizing component B, dissolving in water, and freeze-drying to obtain lyophilized powder.
6. The composition of claim 1, wherein the coprinus japonicus extract is prepared according to the following method:
pulverizing whole plant of Coprinus cinereus, extracting with 95% ethanol as extraction solvent by continuous reflux method, concentrating into extract, dispersing in water, extracting with ethyl acetate and n-butanol respectively, collecting two-phase solvent, spin drying, and mixing to obtain Coprinus cinereus dry extract.
7. The composition as claimed in claim 1, wherein the extract of volatile oil of Chimonanthus praecox is prepared by the following method:
crushing the rhizome of the plant of Chimonanthus praecox, and extracting for 9.5-10.5 h by using a steam extraction method to obtain the volatile oil extract of the Chimonanthus praecox.
8. The composition of claim 1, wherein the saussurea bracteata extract is prepared by the following method:
pulverizing the whole plant of saussurea involucrata, extracting with 80% ethanol as extraction solvent, concentrating into extract, dispersing in water, extracting with n-butanol, and spin drying to obtain saussurea involucrata extract.
9. The composition as claimed in claim 1, wherein said extract of single wood is preferably prepared according to the following process:
pulverizing rhizome of Monostroma nitidum plant, extracting with 95% ethanol as extraction solvent by continuous reflux method, concentrating into extract, dispersing in water, extracting with petroleum ether and ethyl acetate respectively, collecting two-phase solvent, spin drying, and mixing to obtain Monostroma nitidum extract.
10. Use of a composition according to any one of claims 1 to 9 in the preparation of an anti-tumor medicament.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111109677.5A CN113713028A (en) | 2021-09-18 | 2021-09-18 | Composition with effect of inhibiting activity of tumor cells and application thereof |
| PCT/CN2021/138251 WO2023040094A1 (en) | 2021-09-18 | 2021-12-15 | Composition having effect of inhibition of tumor cell activity and application of composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111109677.5A CN113713028A (en) | 2021-09-18 | 2021-09-18 | Composition with effect of inhibiting activity of tumor cells and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113713028A true CN113713028A (en) | 2021-11-30 |
Family
ID=78684596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111109677.5A Pending CN113713028A (en) | 2021-09-18 | 2021-09-18 | Composition with effect of inhibiting activity of tumor cells and application thereof |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN113713028A (en) |
| WO (1) | WO2023040094A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023040094A1 (en) * | 2021-09-18 | 2023-03-23 | 海南鑫开源医药科技有限公司 | Composition having effect of inhibition of tumor cell activity and application of composition |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1506051A (en) * | 2002-12-10 | 2004-06-23 | 吉林天药科技股份有限公司 | Antitumor use of diosgenin |
| CN105535206A (en) * | 2015-12-29 | 2016-05-04 | 青岛蓝图文化传播有限公司市南分公司 | Traditional Chinese medicine formula for treating oral herpes |
| CN105970330A (en) * | 2016-05-14 | 2016-09-28 | 陆建益 | Sea mud/plant composite bacteria inhibiting and whitening polypropylene fibers and preparation method thereof |
| CN106236809A (en) * | 2016-08-30 | 2016-12-21 | 青海民族大学 | Saus-surea obvallata (DC.) Edgew effective site and its preparation method and application |
| CN106943396A (en) * | 2015-12-01 | 2017-07-14 | 哈尔滨凝昇科技有限公司 | Applications of the water ghost new alkali A of any of several broadleaf plants in antineoplastic is prepared |
| CN112979744A (en) * | 2021-02-18 | 2021-06-18 | 齐齐哈尔医学院 | Diosgenin mosaic nitrogen mustard derivative with anti-tumor activity and preparation method and application thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3123745B2 (en) * | 1990-03-16 | 2001-01-15 | 三和生薬株式会社 | Anticancer drug |
| US5569673A (en) * | 1994-05-24 | 1996-10-29 | Purdue Research Foundation | Capsacinoid compounds as proliferation inhibitors |
| US7192612B2 (en) * | 2001-02-22 | 2007-03-20 | Purdue Research Foundation | Compositions and methods based on synergies between capsicum extracts and tea catechins for prevention and treatment of cancer |
| CN102225937B (en) * | 2011-05-04 | 2012-07-25 | 中国科学院昆明植物研究所 | Antineoplastic alkaloid compound, and its medicine composition, preparation method and application |
| CN110343114A (en) * | 2019-08-09 | 2019-10-18 | 昆明医科大学 | A kind of method for separating and preparing of water ghost any of several broadleaf plants alkali |
| CN113713028A (en) * | 2021-09-18 | 2021-11-30 | 海南鑫开源医药科技有限公司 | Composition with effect of inhibiting activity of tumor cells and application thereof |
-
2021
- 2021-09-18 CN CN202111109677.5A patent/CN113713028A/en active Pending
- 2021-12-15 WO PCT/CN2021/138251 patent/WO2023040094A1/en unknown
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1506051A (en) * | 2002-12-10 | 2004-06-23 | 吉林天药科技股份有限公司 | Antitumor use of diosgenin |
| CN106943396A (en) * | 2015-12-01 | 2017-07-14 | 哈尔滨凝昇科技有限公司 | Applications of the water ghost new alkali A of any of several broadleaf plants in antineoplastic is prepared |
| CN105535206A (en) * | 2015-12-29 | 2016-05-04 | 青岛蓝图文化传播有限公司市南分公司 | Traditional Chinese medicine formula for treating oral herpes |
| CN105970330A (en) * | 2016-05-14 | 2016-09-28 | 陆建益 | Sea mud/plant composite bacteria inhibiting and whitening polypropylene fibers and preparation method thereof |
| CN106236809A (en) * | 2016-08-30 | 2016-12-21 | 青海民族大学 | Saus-surea obvallata (DC.) Edgew effective site and its preparation method and application |
| CN112979744A (en) * | 2021-02-18 | 2021-06-18 | 齐齐哈尔医学院 | Diosgenin mosaic nitrogen mustard derivative with anti-tumor activity and preparation method and application thereof |
Non-Patent Citations (6)
| Title |
|---|
| 侯娟娟，等: "辣椒素经内质网应激反应途径诱导K562/ADM耐药细胞凋亡", 《中国临床药理学与治疗学》 * |
| 唐本钦，等: "海南狗牙花的化学成分和药理活性研究进展", 《中药材》 * |
| 林懋祖: "铁筷子脂类的生物活性", 《中成药》 * |
| 肖秀玲，等: "中药有效成分抗肿瘤作用研究进展", 《内蒙古中医药》 * |
| 陈思浩，等: "合成辣素的制备与应用", 《农药》 * |
| 马楠楠，等: "水鬼蕉生物碱抗肿瘤研究进展", 《黑龙江医药》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023040094A1 (en) * | 2021-09-18 | 2023-03-23 | 海南鑫开源医药科技有限公司 | Composition having effect of inhibition of tumor cell activity and application of composition |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023040094A1 (en) | 2023-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2977446B1 (en) | Method for inducing pluripotent stem cells and pluripotent stem cells prepared by said method | |
| EP2635127B1 (en) | Combination therapy for prostate cancer using botanical compositions and bicalutamide | |
| KR20160064966A (en) | Medical composition and applications thereof used for secondary chemotherapy drugs | |
| CN113713028A (en) | Composition with effect of inhibiting activity of tumor cells and application thereof | |
| EP3003490B1 (en) | Combination therapy for prostate cancer using botanical compositions and docetaxel | |
| CN110302221B (en) | Total alkaloid of ailanthus root bark and preparation method and application thereof | |
| CN102961443B (en) | Rhizoma menispermi antineoplastic extract, Preparation method and use | |
| KR20220020147A (en) | Method for preparing Phellinus linteus mycelia extract or Phellinus linteus mycelia extract powder and composition for enhancing immunity comprising them as an active ingredient | |
| CN100427099C (en) | Juglans mandshurica maxim pdysaccharide preparation capable of effectively treating brain cancer and its preapring method | |
| Rashid | Detection of insulin-like protein and some active compounds in Bauhinia variegata Linn. leaf ethanolic extracts and the effect in reducing blood glucose levels in Mice | |
| CN101711790A (en) | Wild Juglans mandshurica bark water extract used for curing liver cancer | |
| JPH0930983A (en) | Apoptosis inhibitor | |
| KR101772954B1 (en) | A anticancer pharmaceutical composition comprising herbal mixture extract of akebia quinata seed extract and panax ginseng, and lipopolysacharide | |
| KR20190119020A (en) | A composition for anti-inflammation comprising hemistepta lyrata extract | |
| KR101209646B1 (en) | Pharmaceutical compositions containing the extracts of Araneus ventricosus for increasing immune cell number or inhibiting metastasis of cancer or proliferation of hepatitis virus | |
| US20070020346A1 (en) | Botanical anticancer formulations | |
| KR20180090197A (en) | Composition comprising the extract of buckwheat for immune activity | |
| CN103083376B (en) | Can be used for the Rhizoma Ligustici extract for the treatment of rhinitis | |
| KR102249737B1 (en) | Compositon comprising the 8-methoxyobliquin compound isolated from Helianthus tuberosus leaves MeOH extraction for preventing or treating immune checkpoint inhibitor | |
| CN109867657B (en) | Dihydroxydibenzo [ b, f ] [1,5] dioxacin ring compound, preparation method, pharmaceutical composition and application thereof | |
| WO2009074065A1 (en) | Use of daphne primeverose genkwanine and daphne plants | |
| CN107929344B (en) | Lithospermum compound composition for preventing and treating laryngeal cancer | |
| KR101220455B1 (en) | Pharmaceutical compositions containing the extracts of Araneus ventricosus for increasing immune cell number | |
| CN116920006A (en) | South Africa leaf extract and application thereof | |
| CN104523740A (en) | Method for preparing selaginella doederleinii hieron polysaccharide extract product and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211130 |